With the Risk Sharing Agreement (RSA) contracts for major anticancer drugs soon to expire, stakeholders (government, pharmaceutical companies, patients) are faced with mixed concerns over the successful renewal of their RSA deals.

In particular, the tension is tigher among pharmaceutical companies that have received or are planning to receive expanded reimbursement for their drugs during their RSA term or has upcoming reevaluations for latecomer drugs within the second half of this year.

Such drugs include famous drugs such as Pfizer’s first-in-class CDK4/6 inhibitor ‘Ibrance (Palbociclib),’ MSD’s PD-1 inhibitor immunotherapy ‘Keytruda (pembrolizumab).’ And Ono·BMS’s ‘Obdivo (ni